Yesterday, April 27, 2016, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $147.00 to $15,185,780.00.

Highlighted Stocks Traded by Insiders:

Summit Midstream Partners (SMLP) - FREE Research Report

Degeyter Brock M, who is Officer at Summit Midstream Partners, sold 6,250 shares at $20.06 on April 27, 2016. Following this transaction, the Officer owned 27,220 shares meaning that the stake was reduced by 18.67% with the 6,250-share transaction.

The shares most recently traded at $40.00, up $19.94, or 49.86% since the insider transaction. Historical insider transactions for Summit Midstream Partners go as follows:

  • 4-Week # shares bought: 75,883
  • 4-Week # shares sold: 1,553
  • 12-Week # shares bought: 75,883
  • 12-Week # shares sold: 1,553
  • 24-Week # shares bought: 151,160
  • 24-Week # shares sold: 1,553

The average volume for Summit Midstream Partners has been 34,600 shares per day over the past 30 days. Summit Midstream Partners has a market cap of $1.2 billion and is part of the utilities sector and utilities industry.

Summit Midstream Partners, LP focuses on owning, developing, and operating midstream energy infrastructure assets primarily shale formations in North America. The company provides natural gas gathering, treating, and processing services.

Exclusive Offer: Get the latest Stock Analysis on SMLP - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Durect (DRRX) - FREE Research Report

21 April Fund, Ltd., who is 10% Owner at Durect, bought 5.5 million shares at $1.25 on April 27, 2016. Following this transaction, the 10% Owner owned 19.9 million shares meaning that the stake was boosted by 38.24% with the 5.5 million-share transaction.

The shares most recently traded at $1.45, up $0.20, or 13.79% since the insider transaction. Historical insider transactions for Durect go as follows:

  • 4-Week # shares bought: 300,100
  • 12-Week # shares bought: 300,100
  • 24-Week # shares bought: 300,100

The average volume for Durect has been 374,100 shares per day over the past 30 days. Durect has a market cap of $163.6 million and is part of the health care sector and drugs industry. Shares are down 33.48% year-to-date as of the close of trading on Wednesday.

DURECT Corporation, a biopharmaceutical company, researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms. Currently, there are 2 analysts who rate Durect a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DRRX - FREE

TheStreet Quant Ratings rates Durect as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself, feeble growth in its earnings per share and generally high debt management risk. Get the full Durect Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medidata Solutions (MDSO) - FREE Research Report

Sherif Tarek, who is Chairman & CEO at Medidata Solutions, sold 7,500 shares at $46.36 on April 27, 2016. Following this transaction, the Chairman & CEO owned 935,321 shares meaning that the stake was reduced by 0.8% with the 7,500-share transaction.

Schloss Eileen, who is Evp, Human Resources at Medidata Solutions, sold 68,717 shares at $46.53 on April 27, 2016. Following this transaction, the Evp, Human Resources owned 22,361 shares meaning that the stake was reduced by 75.45% with the 68,717-share transaction.

The shares most recently traded at $45.54, down $0.99, or 2.17% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 10,201
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 10,201
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 10,201

The average volume for Medidata Solutions has been 523,400 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.6 billion and is part of the technology sector and computer software & services industry. Shares are down 7.43% year-to-date as of the close of trading on Wednesday.

Medidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 142.6. Currently, there are 8 analysts who rate Medidata Solutions a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including premium valuation, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.